{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:59Z","timestamp":1792788479415,"version":"4.5.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Northeastern University USA","id":[{"id":"https:\/\/ror.org\/04t5xt781","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03552-x","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:07:56Z","timestamp":1790705276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating Surfactant Selection in In Vitro Dissolution Testing: Mechanistic Insights and Practical Strategies"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4337-1632","authenticated-orcid":false,"given":"Sushesh Srivatsa","family":"Palakurthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-4251","authenticated-orcid":false,"given":"Niloufar","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9504-8650","authenticated-orcid":false,"given":"Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2225-1005","authenticated-orcid":false,"given":"Sanjaykumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1826-7363","authenticated-orcid":false,"given":"Nikoletta","family":"Fotaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3586-5069","authenticated-orcid":false,"given":"Deanna","family":"Mudie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9736-1171","authenticated-orcid":false,"given":"Sumedha","family":"Kapre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4821-1327","authenticated-orcid":false,"given":"Pradnya","family":"Bapat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7913-0856","authenticated-orcid":false,"given":"Christopher","family":"Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-5914","authenticated-orcid":false,"given":"David B.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6199-9186","authenticated-orcid":false,"given":"Omid","family":"Arjmandi-Tash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9225-0896","authenticated-orcid":false,"given":"Zizhao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3398-8890","authenticated-orcid":false,"given":"Shriram M.","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2012-930X","authenticated-orcid":false,"given":"Karina I.","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1450-8780","authenticated-orcid":false,"given":"Vivian","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"3552_CR1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1023\/a:1015909716312","volume":"6","author":"VP Shah","year":"1989","unstructured":"Shah VP, Konecny JJ, Everett RL, McCullough B, Noorizadeh AC, Skelly JP. In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants. Pharm Res. 1989;6:612\u20138. https:\/\/doi.org\/10.1023\/a:1015909716312.","journal-title":"Pharm Res"},{"key":"3552_CR2","unstructured":"FDA. Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. U.S. Department of Health and Human Services. 1997. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/dissolution-testing-immediate-release-solid-oral-dosage-forms."},{"key":"3552_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14227\/DT120405P6","volume":"12","author":"C Brown","year":"2005","unstructured":"Brown C, Chokshi H, Nickerson B, Reed R, Rohrs B, Shah P. Acceptable analytical practices for dissolution testing of poorly soluble compounds. Dissolut Technol. 2005;12:6\u201312. https:\/\/doi.org\/10.14227\/DT120405P6.","journal-title":"Dissolut Technol"},{"key":"3552_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14227\/DT210314P6","volume":"21","author":"J Dressman","year":"2014","unstructured":"Dressman J. Evolution of dissolution media over the last twenty years. Dissolut Technol. 2014;21:6\u201312. https:\/\/doi.org\/10.14227\/DT210314P6.","journal-title":"Dissolut Technol"},{"key":"3552_CR5","doi-asserted-by":"publisher","first-page":"918","DOI":"10.2174\/1567201815666180116090910","volume":"15","author":"M Kazi","year":"2018","unstructured":"Kazi M, Amri RA, Alanazi FK, Hussain MD. In vitro methods for in vitro-in vivo correlation (IVIVC) for poorly water soluble drugs: lipid based formulation perspective. Curr Drug Deliv. 2018;15:918\u201329. https:\/\/doi.org\/10.2174\/1567201815666180116090910.","journal-title":"Curr Drug Deliv"},{"key":"3552_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/a:1016212804288","volume":"12","author":"GL Amidon","year":"1995","unstructured":"Amidon GL, Lennern\u00e4s H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413\u201320. https:\/\/doi.org\/10.1023\/a:1016212804288.","journal-title":"Pharm Res"},{"key":"3552_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14227\/DT200313P6","volume":"20","author":"N Fotaki","year":"2013","unstructured":"Fotaki N, Brown W, Kochling J, Chokshi H, Miao H, Tang K, et al. Rationale for selection of dissolution media: three case studies. Dissolut Technol. 2013;20:6\u201313. https:\/\/doi.org\/10.14227\/DT200313P6.","journal-title":"Dissolut Technol"},{"key":"3552_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1039\/CS9942300417","volume":"23","author":"MJ Lawrence","year":"1994","unstructured":"Lawrence MJ. Surfactant systems: their use in drug delivery. Chem Soc Rev. 1994;23:417\u201324. https:\/\/doi.org\/10.1039\/CS9942300417.","journal-title":"Chem Soc Rev"},{"key":"3552_CR9","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.1021\/acs.molpharmaceut.8b00884","volume":"15","author":"Z Vinarov","year":"2018","unstructured":"Vinarov Z, Katev V, Burdzhiev N, Tcholakova S, Denkov N. Effect of surfactant-bile interactions on the solubility of hydrophobic drugs in biorelevant dissolution media. Mol Pharm. 2018;15:5741\u201353. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00884.","journal-title":"Mol Pharm"},{"key":"3552_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1021\/js960105t","volume":"86","author":"JR Crison","year":"1997","unstructured":"Crison JR, Weiner ND, Amidon GL. Dissolution media for in vitro testing of water-insoluble drugs: effect of surfactant purity and electrolyte on in vitro dissolution of carbamazepine in aqueous solutions of sodium lauryl sulfate. J Pharm Sci. 1997;86:384\u20138. https:\/\/doi.org\/10.1021\/js960105t.","journal-title":"J Pharm Sci"},{"key":"3552_CR11","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s11095-008-9822-x","volume":"26","author":"V Gray","year":"2009","unstructured":"Gray V, Kelly G, Xia M, Butler C, Thomas S, Mayock S. The science of USP 1 and 2 dissolution: present challenges and future relevance. Pharm Res. 2009;26:1289\u2013302. https:\/\/doi.org\/10.1007\/s11095-008-9822-x.","journal-title":"Pharm Res"},{"key":"3552_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.14227\/DT160309P21","volume":"16","author":"E Jantratid","year":"2009","unstructured":"Jantratid E, Dressman J. Biorelevant dissolution media simulating the proximal human gastrointestinal tract: an update. Dissolution Technol. 2009;16:21\u20135. https:\/\/doi.org\/10.14227\/DT160309P21.","journal-title":"Dissolution Technol"},{"key":"3552_CR13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1021\/mp100049m","volume":"7","author":"JH Fagerberg","year":"2010","unstructured":"Fagerberg JH, Tsinman O, Sun N, Tsinman K, Avdeef A, Bergstr\u00f6m CAS. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. Mol Pharm. 2010;7:1419\u201330. https:\/\/doi.org\/10.1021\/mp100049m.","journal-title":"Mol Pharm"},{"key":"3552_CR14","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1021\/mp100149j","volume":"7","author":"DM Mudie","year":"2010","unstructured":"Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing. Mol Pharm. 2010;7:1388\u2013405. https:\/\/doi.org\/10.1021\/mp100149j.","journal-title":"Mol Pharm"},{"key":"3552_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1208\/s12248-018-0288-4","volume":"21","author":"A Abend","year":"2019","unstructured":"Abend A, Curran D, Kuiper J, Lu X, Li H, Hermans A, et al. Dissolution Testing in Drug Product Development: Workshop Summary Report. AAPS J. 2019;21:21. https:\/\/doi.org\/10.1208\/s12248-018-0288-4.","journal-title":"AAPS J"},{"key":"3552_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijpharm.2011.04.018","volume":"412","author":"SN Bhattachar","year":"2011","unstructured":"Bhattachar SN, Risley DS, Werawatganone P, Aburub A. Weak bases and formation of a less soluble lauryl sulfate salt\/complex in sodium lauryl sulfate (SLS) containing media. Int J Pharm. 2011;412:95\u20138. https:\/\/doi.org\/10.1016\/j.ijpharm.2011.04.018.","journal-title":"Int J Pharm"},{"key":"3552_CR17","unstructured":"Research C for DE and. Dissolution Testing of Immediate Release Solid Oral Dosage Forms [Internet]. FDA; 2019 [cited 2025 Nov 7]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/dissolution-testing-immediate-release-solid-oral-dosage-forms. Accessed 7 Nov 2025"},{"key":"3552_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ijpharm.2006.05.004","volume":"321","author":"S-H Park","year":"2006","unstructured":"Park S-H, Choi H-K. The effects of surfactants on the dissolution profiles of poorly water-soluble acidic drugs. Int J Pharm. 2006;321:35\u201341. https:\/\/doi.org\/10.1016\/j.ijpharm.2006.05.004.","journal-title":"Int J Pharm"},{"key":"3552_CR19","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/cite.201100256","volume":"84","author":"T Ingram","year":"2012","unstructured":"Ingram T, Storm S, Glembin P, Bendt S, Huber D, Mehling T, et al. Aqueous surfactant two-phase systems for the continuous countercurrent cloud point extraction. Chem Ing Tech. 2012;84:840\u20138. https:\/\/doi.org\/10.1002\/cite.201100256.","journal-title":"Chem Ing Tech"},{"key":"3552_CR20","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1007\/s11095-006-9104-4","volume":"23","author":"G Dumortier","year":"2006","unstructured":"Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res. 2006;23:2709\u201328. https:\/\/doi.org\/10.1007\/s11095-006-9104-4.","journal-title":"Pharm Res"},{"key":"3552_CR21","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/jps.23852","volume":"103","author":"D Desai","year":"2014","unstructured":"Desai D, Wong B, Huang Y, Ye Q, Tang D, Guo H, et al. Surfactant-mediated dissolution of metformin hydrochloride tablets: wetting effects versus ion pairs diffusivity. J Pharm Sci. 2014;103:920\u20136. https:\/\/doi.org\/10.1002\/jps.23852.","journal-title":"J Pharm Sci"},{"key":"3552_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122035","volume":"624","author":"Z Lin","year":"2022","unstructured":"Lin Z, Pang Z, Zhang K, Qian Z, Liu Z, Zhang J, et al. Effect of sodium lauryl sulfate-mediated gelation on the suppressed dissolution of crystalline lurasidone hydrochloride and a strategy to mitigate the gelation. Int J Pharm. 2022;624:122035. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122035.","journal-title":"Int J Pharm"},{"key":"3552_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.rinphs.2013.08.001","volume":"3","author":"P Kn\u00f6\u00f6s","year":"2013","unstructured":"Kn\u00f6\u00f6s P, Onder S, Pedersen L, Piculell L, Ulvenlund S, Wahlgren M. Surfactants modify the release from tablets made of hydrophobically modified poly (acrylic acid). Results Pharma Sci. 2013;3:7\u201314. https:\/\/doi.org\/10.1016\/j.rinphs.2013.08.001.","journal-title":"Results Pharma Sci"},{"key":"3552_CR24","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1007\/s11095-023-03491-3","volume":"40","author":"A Newman","year":"2023","unstructured":"Newman A, Zografi G. Perspectives on the wetting of solids in pharmaceutical systems. Pharm Res. 2023;40:3099\u2013118. https:\/\/doi.org\/10.1007\/s11095-023-03491-3.","journal-title":"Pharm Res"},{"key":"3552_CR25","doi-asserted-by":"publisher","unstructured":"Aisha, Batool I, Iftekhar S, Taj MB, Carabineiro SAC, Ahmad F, et al. Wetting the surface: A deep dive into chemistry and applications of surfactants. Clean Chem Eng. 2025;11:100197. https:\/\/doi.org\/10.1016\/j.clce.2025.100197","DOI":"10.1016\/j.clce.2025.100197"},{"key":"3552_CR26","unstructured":"Buckley RT. Surfactant-Mediated Dissolution of Poorly Soluble Drug Substances [Internet]. Kalamazoo College; 2005 [cited 2025 Nov 7]. http:\/\/hdl.handle.net\/10920\/12663. Accessed 7 Nov 2025"},{"key":"3552_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijpharm.2006.03.001","volume":"317","author":"SM Wong","year":"2006","unstructured":"Wong SM, Kellaway IW, Murdan S. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm. 2006;317:61\u20138. https:\/\/doi.org\/10.1016\/j.ijpharm.2006.03.001.","journal-title":"Int J Pharm"},{"key":"3552_CR28","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03639045.2016.1185436","volume":"42","author":"B Yang","year":"2016","unstructured":"Yang B, Xu L, Wang Q, Li S. Modulation of the wettability of excipients by surfactant and its impacts on the disintegration and release of tablets. Drug Dev Ind Pharm. 2016;42:1945\u201355. https:\/\/doi.org\/10.1080\/03639045.2016.1185436.","journal-title":"Drug Dev Ind Pharm"},{"key":"3552_CR29","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/j.2042-7158.2010.01023.x","volume":"62","author":"K Kleberg","year":"2010","unstructured":"Kleberg K, Jacobsen J, M\u00fcllertz A. Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies. J Pharm Pharmacol. 2010;62:1656\u201368. https:\/\/doi.org\/10.1111\/j.2042-7158.2010.01023.x.","journal-title":"J Pharm Pharmacol"},{"key":"3552_CR30","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/jps.20118","volume":"93","author":"A Balakrishnan","year":"2004","unstructured":"Balakrishnan A, Rege BD, Amidon GL, Polli JE. Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. J Pharm Sci. 2004;93:2064\u201375. https:\/\/doi.org\/10.1002\/jps.20118.","journal-title":"J Pharm Sci"},{"key":"3552_CR31","doi-asserted-by":"publisher","unstructured":"Jinno J, Oh D m, Crison JR, Amidon GL. Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J Pharm Sci. 2000;89:268\u201374. https:\/\/doi.org\/10.1002\/(SICI)1520-6017(200002)89:2%3C268::AID-JPS14%3E3.0.CO;2-F","DOI":"10.1002\/(SICI)1520-6017(200002)89:2%3C268::AID-JPS14%3E3.0.CO;2-F"},{"key":"3552_CR32","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ejpb.2006.10.010","volume":"66","author":"C Alvarez-Lorenzo","year":"2007","unstructured":"Alvarez-Lorenzo C, Gonzalez-Lopez J, Fernandez-Tarrio M, Sandez-Macho I, Concheiro A. Tetronic micellization, gelation and drug solubilization: influence of pH and ionic strength. Eur J Pharm Biopharm. 2007;66:244\u201352. https:\/\/doi.org\/10.1016\/j.ejpb.2006.10.010.","journal-title":"Eur J Pharm Biopharm"},{"key":"3552_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molliq.2018.04.054","volume":"262","author":"M Jabbari","year":"2018","unstructured":"Jabbari M, Teymoori F. An insight into effect of micelle-forming surfactants on aqueous solubilization and octanol\/water partition coefficient of the drugs gemfibrozil and ibuprofen. J Mol Liq. 2018;262:1\u20137. https:\/\/doi.org\/10.1016\/j.molliq.2018.04.054.","journal-title":"J Mol Liq"},{"key":"3552_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/js9601896","volume":"86","author":"BC Hancock","year":"1997","unstructured":"Hancock BC, Zografi G. Characteristics and Significance of the Amorphous State in Pharmaceutical Systems. J Pharm Sci. 1997;86:1\u201312. https:\/\/doi.org\/10.1021\/js9601896.","journal-title":"J Pharm Sci"},{"key":"3552_CR35","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1211\/jpp\/61.12.0001","volume":"61","author":"S Janssens","year":"2009","unstructured":"Janssens S, Van den Mooter G. Review: physical chemistry of solid dispersions. J Pharm Pharmacol. 2009;61:1571\u201386. https:\/\/doi.org\/10.1211\/jpp\/61.12.0001.","journal-title":"J Pharm Pharmacol"},{"key":"3552_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejpb.2016.03.007","volume":"103","author":"PT Mah","year":"2016","unstructured":"Mah PT, Peltonen L, Novakovic D, Rades T, Strachan CJ, Laaksonen T. The effect of surfactants on the dissolution behavior of amorphous formulations. Eur J Pharm Biopharm. 2016;103:13\u201322. https:\/\/doi.org\/10.1016\/j.ejpb.2016.03.007.","journal-title":"Eur J Pharm Biopharm"},{"key":"3552_CR37","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.xphs.2024.10.023","volume":"114","author":"A Alhalaweh","year":"2025","unstructured":"Alhalaweh A, Sayed ME, Kovac L, Bergstr\u00f6m CAS. Impact of surfactants on solution behavior and membrane transport of amorphous solid dispersions. J Pharm Sci. 2025;114:458\u201367. https:\/\/doi.org\/10.1016\/j.xphs.2024.10.023.","journal-title":"J Pharm Sci"},{"key":"3552_CR38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1021\/mp5006245","volume":"12","author":"J Chen","year":"2015","unstructured":"Chen J, Ormes JD, Higgins JD, Taylor LS. Impact of surfactants on the crystallization of aqueous suspensions of celecoxib amorphous solid dispersion spray dried particles. Mol Pharm. 2015;12:533\u201341. https:\/\/doi.org\/10.1021\/mp5006245.","journal-title":"Mol Pharm"},{"key":"3552_CR39","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1021\/acs.cgd.5c00417","volume":"25","author":"J Zhang","year":"2025","unstructured":"Zhang J, Zhang L, Liu M, Zeng Z. Impact of surfactants as formulation additives and media components on the performance of amorphous solid dispersions. Cryst Growth Des. 2025;25:5561\u201383. https:\/\/doi.org\/10.1021\/acs.cgd.5c00417.","journal-title":"Cryst Growth Des"},{"key":"3552_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10020053","volume":"10","author":"D Feng","year":"2018","unstructured":"Feng D, Peng T, Huang Z, Singh V, Shi Y, Wen T, et al. Polymer\u2013surfactant system based amorphous solid dispersion: precipitation inhibition and bioavailability enhancement of itraconazole. Pharmaceutics. 2018;10:53. https:\/\/doi.org\/10.3390\/pharmaceutics10020053.","journal-title":"Pharmaceutics"},{"key":"3552_CR41","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ijpharm.2017.10.063","volume":"535","author":"Z Huang","year":"2018","unstructured":"Huang Z, Parikh S, Fish WP. Interactions between a poorly soluble cationic drug and sodium dodecyl sulfate in dissolution medium and their impact on in vitro dissolution behavior. Int J Pharm. 2018;535:350\u20139. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.10.063.","journal-title":"Int J Pharm"},{"key":"3552_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105836","volume":"162","author":"N-T Tung","year":"2021","unstructured":"Tung N-T, Tran C-S, Nguyen T-L, Pham T-M-H, Chi S-C, Nguyen H-A, et al. Effect of surfactant on the in vitro dissolution and the oral bioavailability of a weakly basic drug from an amorphous solid dispersion. Eur J Pharm Sci. 2021;162:105836. https:\/\/doi.org\/10.1016\/j.ejps.2021.105836.","journal-title":"Eur J Pharm Sci"},{"key":"3552_CR43","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1021\/mp5006992","volume":"12","author":"G Ottaviani","year":"2015","unstructured":"Ottaviani G, Wendelspiess S, Alvarez-S\u00e1nchez R. Importance of critical micellar concentration for the prediction of solubility enhancement in biorelevant media. Mol Pharm. 2015;12:1171\u20139. https:\/\/doi.org\/10.1021\/mp5006992.","journal-title":"Mol Pharm"},{"key":"3552_CR44","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1016\/j.xphs.2022.09.003","volume":"111","author":"AK Bhattiprolu","year":"2022","unstructured":"Bhattiprolu AK, Kollipara S, Ahmed T, Boddu R, Chachad S. Utility of Physiologically Based Biopharmaceutics Modeling (PBBM) in Regulatory Perspective: Application to Supersede f2, Enabling Biowaivers & Creation of Dissolution Safe Space. J Pharm Sci. 2022;111:3397\u2013410. https:\/\/doi.org\/10.1016\/j.xphs.2022.09.003.","journal-title":"J Pharm Sci"},{"key":"3552_CR45","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1208\/s12248-010-9203-3","volume":"12","author":"S Klein","year":"2010","unstructured":"Klein S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J. 2010;12:397\u2013406. https:\/\/doi.org\/10.1208\/s12248-010-9203-3.","journal-title":"AAPS J"},{"key":"3552_CR46","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1021\/mp200181v","volume":"8","author":"JM Miller","year":"2011","unstructured":"Miller JM, Beig A, Krieg BJ, Carr RA, Borchardt TB, Amidon GE, et al. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol Pharm. 2011;8:1848\u201356. https:\/\/doi.org\/10.1021\/mp200181v.","journal-title":"Mol Pharm"},{"issue":"8","key":"3552_CR47","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1208\/s12249-023-02692-8","volume":"24","author":"H Chen","year":"2023","unstructured":"Chen H, Wang R, McElderry J-D. Discriminative dissolution method development through an aQbD approach. AAPS PharmSciTech. 2023;24:255. https:\/\/doi.org\/10.1208\/s12249-023-02692-8.","journal-title":"AAPS PharmSciTech"},{"key":"3552_CR48","doi-asserted-by":"publisher","unstructured":"Singla N, Gupta GD, Kholi K, Singla AK. A Discriminatory and Biorelevant Dissolution Test Method for Simvastatin Drug Products. Dissolution Technologies. 2009;11\u20133. https:\/\/doi.org\/10.14227\/DT160409P11","DOI":"10.14227\/DT160409P11"},{"key":"3552_CR49","doi-asserted-by":"publisher","DOI":"10.5419\/bjpg2018-0023","author":"TNC Dantas","year":"2019","unstructured":"Dantas TNC, Santanna VC, Souza TTC, Lucas CRS, Neto AAD, Aum PTP. Microemulsions and nanoemulsions applied to well stimulation and enhanced oil recovery (EOR). Braz J Pet Gas. 2019. https:\/\/doi.org\/10.5419\/bjpg2018-0023.","journal-title":"Braz J Pet Gas"},{"key":"3552_CR50","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/geotechnics2030034","volume":"2","author":"S Boduroglu","year":"2022","unstructured":"Boduroglu S, Bashir R. Review of capillary rise experiments for surface-active solutes in the subsurface. Geotech. 2022;2:706\u201330. https:\/\/doi.org\/10.3390\/geotechnics2030034.","journal-title":"Geotech"},{"key":"3552_CR51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.aca.2005.05.069","volume":"548","author":"E Fuguet","year":"2005","unstructured":"Fuguet E, R\u00e0fols C, Ros\u00e9s M, Bosch E. Critical micelle concentration of surfactants in aqueous buffered and unbuffered systems. Anal Chim Acta. 2005;548:95\u2013100. https:\/\/doi.org\/10.1016\/j.aca.2005.05.069.","journal-title":"Anal Chim Acta"},{"key":"3552_CR52","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1021\/je700659g","volume":"53","author":"PA Bhat","year":"2008","unstructured":"Bhat PA, Dar AA, Rather GM. Solubilization capabilities of some cationic, anionic, and nonionic surfactants toward the poorly water-soluble antibiotic drug erythromycin. J Chem Eng Data. 2008;53:1271\u20137. https:\/\/doi.org\/10.1021\/je700659g.","journal-title":"J Chem Eng Data"},{"key":"3552_CR53","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3126\/bibechana.v11i0.10390","volume":"11","author":"A Bhattarai","year":"2014","unstructured":"Bhattarai A, Shrivastav G, Adhikari CN. Study of critical micelle concentration of cetyltrimethylammonium bromide (CTAB) in pure water in presence and absence of magnesium sulphate and sodium sulphae by measuring conductivity meter. BIBECHANA. 2014;11:123\u20137. https:\/\/doi.org\/10.3126\/bibechana.v11i0.10390.","journal-title":"BIBECHANA"},{"key":"3552_CR54","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/jps.2600610842","volume":"61","author":"KL Mittal","year":"1972","unstructured":"Mittal KL. Determination of CMC of polysorbate 20 in aqueous solution by surface tension method. J Pharm Sci. 1972;61:1334\u20135. https:\/\/doi.org\/10.1002\/jps.2600610842.","journal-title":"J Pharm Sci"},{"key":"3552_CR55","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/961739","volume":"9","author":"E Mohajeri","year":"2012","unstructured":"Mohajeri E, Noudeh GD. Effect of Temperature on the Critical Micelle Concentration and Micellization Thermodynamic of Nonionic Surfactants: Polyoxyethylene Sorbitan Fatty Acid Esters. J Chem. 2012;9:961739. https:\/\/doi.org\/10.1155\/2012\/961739.","journal-title":"J Chem"},{"key":"3552_CR56","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ejpb.2014.12.015","volume":"94","author":"AC Braun","year":"2015","unstructured":"Braun AC, Ilko D, Merget B, Gieseler H, Germershaus O, Holzgrabe U, et al. Predicting critical micelle concentration and micelle molecular weight of polysorbate 80 using compendial methods. Eur J Pharm Biopharm. 2015;94:559\u201368. https:\/\/doi.org\/10.1016\/j.ejpb.2014.12.015.","journal-title":"Eur J Pharm Biopharm"},{"key":"3552_CR57","volume-title":"Handbook of Pharmaceutical Excipients","author":"R Rowe","year":"2009","unstructured":"Rowe R, Sheskey P, Quinn M. Handbook of Pharmaceutical Excipients. 6th ed. London, England: APhA; 2009.","edition":"6th ed"},{"key":"3552_CR58","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5650\/jos.58.185","volume":"58","author":"R Kakehashi","year":"2009","unstructured":"Kakehashi R, Tokai N, Maeda H, Yamamura S. Protonation Behavior and Stability of Micelles of N-Lauroylaminoalkyl-Dimethylamine Oxides-Effects of Added Salt Concentration and Spacer Length. J Oleo Sci. 2009;58:185\u201393. https:\/\/doi.org\/10.5650\/jos.58.185.","journal-title":"J Oleo Sci"},{"key":"3552_CR59","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/jps.10216","volume":"91","author":"E Ha","year":"2002","unstructured":"Ha E, Wang W, John Wang Y. Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci. 2002;91:2252\u201364. https:\/\/doi.org\/10.1002\/jps.10216.","journal-title":"J Pharm Sci"},{"key":"3552_CR60","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/jps.20726","volume":"96","author":"WR Wasylaschuk","year":"2007","unstructured":"Wasylaschuk WR, Harmon PA, Wagner G, Harman AB, Templeton AC, Xu H, et al. Evaluation of hydroperoxides in common pharmaceutical excipients. J Pharm Sci. 2007;96:106\u201316. https:\/\/doi.org\/10.1002\/jps.20726.","journal-title":"J Pharm Sci"},{"key":"3552_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2023.100202","volume":"6","author":"J Weber","year":"2023","unstructured":"Weber J, Buske J, M\u00e4der K, Garidel P, Diederichs T. Oxidation of polysorbates \u2013 An underestimated degradation pathway? Int J Pharm X. 2023;6:100202. https:\/\/doi.org\/10.1016\/j.ijpx.2023.100202.","journal-title":"Int J Pharm X"},{"key":"3552_CR62","doi-asserted-by":"publisher","unstructured":"Morker K, Patel R, Purohit D. A Comprehensive Review on the Stability and Degradation of Polysorbates in Biopharmaceuticals. EJPPS Eur J Parenter Pharm Sci. 2025.\u00a0https:\/\/doi.org\/10.37521\/ejpps30301","DOI":"10.37521\/ejpps30301"},{"key":"3552_CR63","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1208\/s12249-012-9759-6","volume":"13","author":"SR Singh","year":"2012","unstructured":"Singh SR, Zhang J, O\u2019Dell C, Hsieh M-C, Goldstein J, Liu J, et al. Effect of polysorbate 80 quality on photostability of a monoclonal antibody. AAPS PharmSciTech. 2012;13:422\u201330. https:\/\/doi.org\/10.1208\/s12249-012-9759-6.","journal-title":"AAPS PharmSciTech"},{"key":"3552_CR64","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.xphs.2022.02.009","volume":"111","author":"K Wuchner","year":"2022","unstructured":"Wuchner K, Yi L, Chery C, Nikels F, Junge F, Crotts G, et al. Industry perspective on the use and characterization of polysorbates for biopharmaceutical products part 1: survey report on current state and common practices for handling and control of polysorbates. J Pharm Sci. 2022;111:1280\u201391. https:\/\/doi.org\/10.1016\/j.xphs.2022.02.009.","journal-title":"J Pharm Sci"},{"key":"3552_CR65","doi-asserted-by":"publisher","unstructured":"Kloefer B, Hoogevest PV, Moloney R, Kuentz M, Leigh M, Dressman JB. Study of a Standardized TaurocholateLecithin Powder for Preparing the Biorelevant Media FeSSIF and FaSSIF. Dissolution Technol. 2010; https:\/\/doi.org\/10.14227\/DT170310P6","DOI":"10.14227\/DT170310P6"},{"key":"3552_CR66","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s11095-008-9569-4","volume":"25","author":"E Jantratid","year":"2008","unstructured":"Jantratid E, Janssen N, Reppas C, Dressman JB. Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update. Pharm Res. 2008;25:1663\u201376. https:\/\/doi.org\/10.1007\/s11095-008-9569-4.","journal-title":"Pharm Res"},{"key":"3552_CR67","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.xphs.2023.11.030","volume":"113","author":"S Kollipara","year":"2024","unstructured":"Kollipara S, Martins FS, Sanghavi M, Santos GML, Saini A, Ahmed T. Role of physiologically based biopharmaceutics modeling (PBBM) in fed bioequivalence study waivers: regulatory outlook, case studies and future perspectives. J Pharm Sci. 2024;113:345\u201358. https:\/\/doi.org\/10.1016\/j.xphs.2023.11.030.","journal-title":"J Pharm Sci"},{"key":"3552_CR68","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s11095-025-03866-8","volume":"42","author":"A Pal","year":"2025","unstructured":"Pal A, Alam K, Stier E, Heimbach T, Cristofoletti R, Al\u2010Gousous J, et al. Assessing impact of food on oral drug bioequivalence supporting ICH M13 A with the advancements of physiologically based pharmacokinetic modeling. Pharm Res. 2025;42:835\u201345. https:\/\/doi.org\/10.1007\/s11095-025-03866-8.","journal-title":"Pharm Res"},{"key":"3552_CR69","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1016\/j.xphs.2016.03.005","volume":"105","author":"PA Elvang","year":"2016","unstructured":"Elvang PA, Hinna AH, Brouwers J, Hens B, Augustijns P, Brandl M. Bile salt micelles and phospholipid vesicles present in simulated and human intestinal fluids: structural analysis by flow field-flow fractionation\/multiangle laser light scattering. J Pharm Sci. 2016;105:2832\u20139. https:\/\/doi.org\/10.1016\/j.xphs.2016.03.005.","journal-title":"J Pharm Sci"},{"key":"3552_CR70","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jpba.2017.07.014","volume":"145","author":"PA Elvang","year":"2017","unstructured":"Elvang PA, Stein PC, Bauer-Brandl A, Brandl M. Characterization of co-existing colloidal structures in fasted state simulated fluids FaSSIF: a comparative study using AF4\/MALLS, DLS and DOSY. J Pharm Biomed Anal. 2017;145:531\u20136. https:\/\/doi.org\/10.1016\/j.jpba.2017.07.014.","journal-title":"J Pharm Biomed Anal"},{"key":"3552_CR71","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1002\/jps.22122","volume":"99","author":"K Kleberg","year":"2010","unstructured":"Kleberg K, Jacobsen F, Fatouros DG, M\u00fcllertz A. Biorelevant media simulating fed state intestinal fluids: colloid phase characterization and impact on solubilization capacity. J Pharm Sci. 2010;99:3522\u201332. https:\/\/doi.org\/10.1002\/jps.22122.","journal-title":"J Pharm Sci"},{"key":"3552_CR72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejpb.2019.04.017","volume":"140","author":"P Berben","year":"2019","unstructured":"Berben P, Ashworth L, Beato S, Bevernage J, Bruel J-L, Butler J, et al. Biorelevant dissolution testing of a weak base: interlaboratory reproducibility and investigation of parameters controlling in vitro precipitation. Eur J Pharm Biopharm. 2019;140:141\u20138. https:\/\/doi.org\/10.1016\/j.ejpb.2019.04.017.","journal-title":"Eur J Pharm Biopharm"},{"key":"3552_CR73","doi-asserted-by":"publisher","DOI":"10.14227\/DT290222P62","author":"DA Silva","year":"2022","unstructured":"Silva DA, Davies NM, Bou-Chacra N, Ferraz HG, Lobenberg R. Update on gastrointestinal biorelevant media and physiologically relevant dissolution conditions. Dissolut Technol. 2022. https:\/\/doi.org\/10.14227\/DT290222P62.","journal-title":"Dissolut Technol"},{"key":"3552_CR74","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14227\/DT260319P6","volume":"26","author":"T Flanagan","year":"2019","unstructured":"Flanagan T, Mann J. Dissolution universal strategy tool (DUST): a tool to guide dissolution method development strategy. Dissolut Technol. 2019;26:6\u201315.","journal-title":"Dissolut Technol"},{"key":"3552_CR75","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1021\/mp500193g","volume":"11","author":"WA Birru","year":"2014","unstructured":"Birru WA, Warren DB, Ibrahim A, Williams HD, Benameur H, Porter CJH, et al. Digestion of phospholipids after secretion of bile into the duodenum changes the phase behavior of bile components. Mol Pharm. 2014;11:2825\u201334. https:\/\/doi.org\/10.1021\/mp500193g.","journal-title":"Mol Pharm"},{"key":"3552_CR76","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1021\/acs.molpharmaceut.7b00198","volume":"14","author":"J Mann","year":"2017","unstructured":"Mann J, Dressman J, Rosenblatt K, Ashworth L, Muenster U, Frank K, et al. Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study. Mol Pharm. 2017;14:4192\u2013201. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00198.","journal-title":"Mol Pharm"},{"key":"3552_CR77","unstructured":"Dissolution Methods [Internet]. [cited 2026 Apr 26]. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/dissolution\/dsp_getallData.cfm. Accessed 26 Apr 2026"},{"key":"3552_CR78","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1124\/pr.112.005660","volume":"65","author":"HD Williams","year":"2013","unstructured":"Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65:315\u2013499. https:\/\/doi.org\/10.1124\/pr.112.005660.","journal-title":"Pharmacol Rev"},{"key":"3552_CR79","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/ijn.s595","volume":"3","author":"J-U Junghanns","year":"2008","unstructured":"Junghanns J-U, M\u00fcller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3:295\u2013309. https:\/\/doi.org\/10.2147\/ijn.s595.","journal-title":"Int J Nanomedicine"},{"key":"3552_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.rinma.2024.100573","volume":"22","author":"P Koli","year":"2024","unstructured":"Koli P. UV\u2013visible spectroscopic exploratory insight into the long term photo-stability of the fast green FCF dye-fructose-sodium lauryl sulphate-NaOH electrolyte based photogalvanic cell. Results in Materials. 2024;22:100573. https:\/\/doi.org\/10.1016\/j.rinma.2024.100573.","journal-title":"Results in Materials"},{"key":"3552_CR81","doi-asserted-by":"publisher","unstructured":"Micelle Formation by Surfactants. Surfactants and Interfacial Phenomena [Internet]. John Wiley & Sons, Ltd; 2012 [cited 2025 Nov 8]. p. 123\u2013201. https:\/\/doi.org\/10.1002\/9781118228920.ch3","DOI":"10.1002\/9781118228920.ch3"},{"key":"3552_CR82","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1021\/acs.molpharmaceut.1c00690","volume":"19","author":"Y Guo","year":"2022","unstructured":"Guo Y, Sun CC. Pharmaceutical lauryl sulfate salts: prevalence, formation rules, and formulation implications. Mol Pharm. 2022;19:432\u20139. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00690.","journal-title":"Mol Pharm"},{"key":"3552_CR83","unstructured":"General Chapter <1092> The Dissolution Procedure: Development and Validation [Internet]. USP-NF; 2013. https:\/\/www.uspnf.com\/notices\/general-chapter-dissolution-procedure-development-and-validation"},{"key":"3552_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2023.109040","volume":"193","author":"CJ Tereba-Mamani","year":"2023","unstructured":"Tereba-Mamani CJ, Ruiz-Angel MJ, Baeza-Baeza JJ, Garc\u00eda-Alvarez-Coque MC. Chromatographic behavior of polar compounds in the transition between reversed-phase and submicellar\/micellar liquid chromatography. Microchem J. 2023;193:109040. https:\/\/doi.org\/10.1016\/j.microc.2023.109040.","journal-title":"Microchem J"},{"key":"3552_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2025.115954","volume":"219","author":"C Cuenca-Serrano","year":"2025","unstructured":"Cuenca-Serrano C, Peris-Vicente J, Garc\u00eda-Alvarez-Coque MC, Ruiz-Angel MJ. Mixed micellar liquid chromatography with polyoxyethylene(10)tridecyl ether and sodium dodecyl sulphate: an organic solvent-free approach. Microchem J. 2025;219:115954. https:\/\/doi.org\/10.1016\/j.microc.2025.115954.","journal-title":"Microchem J"},{"key":"3552_CR86","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0731-7085(85)80073-X","volume":"3","author":"ID Watson","year":"1985","unstructured":"Watson ID, Stewart MJ, Farid YYZ. The effect of surfactants on the high-performance liquid chromatography of anthracyclines. J Pharm Biomed Anal. 1985;3:555\u201363. https:\/\/doi.org\/10.1016\/0731-7085(85)80073-X.","journal-title":"J Pharm Biomed Anal"},{"key":"3552_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3401","volume":"40","author":"J Ren","year":"2024","unstructured":"Ren J, Zhang Y, Wang C. Understanding adsorption behavior of polysorbate-20 to sterile filters in therapeutic proteins final filtration process. Biotechnol Prog. 2024;40:e3401. https:\/\/doi.org\/10.1002\/btpr.3401.","journal-title":"Biotechnol Prog"},{"key":"3552_CR88","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1021\/acs.molpharmaceut.7b00406","volume":"14","author":"SM Pathak","year":"2017","unstructured":"Pathak SM, Ruff A, Kostewicz ES, Patel N, Turner DB, Jamei M. Model-based analysis of biopharmaceutic experiments to improve mechanistic oral absorption modeling: an integrated in vitro in vivo extrapolation perspective using ketoconazole as a model drug. Mol Pharm. 2017;14:4305\u201320. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00406.","journal-title":"Mol Pharm"},{"key":"3552_CR89","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2434-1","volume":"35","author":"L Vuleti\u0107","year":"2018","unstructured":"Vuleti\u0107 L, Khan MZI, \u0160poljari\u0107 D, Radi\u0107 M, Cetina-\u010ci\u017emek B, Filipovi\u0107-Gr\u010di\u0107 J. Development of a clinically relevant dissolution method for metaxalone immediate release formulations based on an IVIVC model. Pharm Res. 2018;35:163. https:\/\/doi.org\/10.1007\/s11095-018-2434-1.","journal-title":"Pharm Res"},{"key":"3552_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2025.107052","volume":"208","author":"RP Patel","year":"2025","unstructured":"Patel RP, Nordquist EB, Polli JE. Prediction of surfactant-mediated dissolution of poorly soluble drugs from drug powder. Eur J Pharm Sci. 2025;208:107052. https:\/\/doi.org\/10.1016\/j.ejps.2025.107052.","journal-title":"Eur J Pharm Sci"},{"key":"3552_CR91","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1208\/s12248-008-9034-7","volume":"10","author":"PA Dickinson","year":"2008","unstructured":"Dickinson PA, Lee WW, Stott PW, Townsend AI, Smart JP, Ghahramani P, et al. Clinical Relevance of Dissolution Testing in Quality by Design. AAPS J. 2008;10:380\u201390. https:\/\/doi.org\/10.1208\/s12248-008-9034-7.","journal-title":"AAPS J"},{"key":"3552_CR92","doi-asserted-by":"publisher","unstructured":"Rahman ML, Mamun MA, Ahamed A, Kabir M, Dinehkaboudi FN, Zangeneh M, et al. Advanced Dissolution Testing for Novel Drug Formulations: Challenges, Emerging Methods, and Regulatory Perspectives. Journal of Angiotherapy. Eman Research Publishing LLC, USA; 2025;9:1\u201316. https:\/\/doi.org\/10.25163\/biomedical.9110245","DOI":"10.25163\/biomedical.9110245"},{"key":"3552_CR93","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1208\/s12248-017-0085-5","volume":"19","author":"N Bou-Chacra","year":"2017","unstructured":"Bou-Chacra N, Melo KJC, Morales IAC, Stippler ES, Kesisoglou F, Yazdanian M, et al. Evolution of choice of solubility and dissolution media after two decades of biopharmaceutical classification system. AAPS J. 2017;19:989\u20131001. https:\/\/doi.org\/10.1208\/s12248-017-0085-5.","journal-title":"AAPS J"},{"key":"3552_CR94","unstructured":"FDA. M9 Biopharmaceutics Classification SystemBased Biowaivers. U.S. Department of Health and Human Services. 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m9-biopharmaceutics-classification-system-based-biowaivers."},{"key":"3552_CR95","unstructured":"FDA. M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver [Internet]. U.S. Department of Health and Human Services.; 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m13b-bioequivalence-immediate-release-solid-oral-dosage-forms-additional-strengths-biowaiver"},{"key":"3552_CR96","unstructured":"FDA. Dissolution Methods Database [Internet]. U.S. Department of Health and Human Services. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/dissolution\/. Accessed Aug 2026."},{"key":"3552_CR97","unstructured":"FDA. M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms [Internet]. U.S. Department of Health and Human Services.; 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m13a-bioequivalence-immediate-release-solid-oral-dosage-forms"},{"key":"3552_CR98","unstructured":"EMA. Guideline on the investigation of bioequivalence (CPMP\/EWP\/QWP\/1401\/98 Rev. 1). Eur Med Agency. 2010. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf."},{"key":"3552_CR99","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Guidelines for Bioequivalence Studies of Generic Products. Tokyo, Japan. 2012. https:\/\/www.nihs.go.jp\/drug\/be-guide(e)\/2020\/GL1_BE_2020.pdf."},{"key":"3552_CR100","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1023\/a:1011984216775","volume":"15","author":"JB Dressman","year":"1998","unstructured":"Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998;15:11\u201322. https:\/\/doi.org\/10.1023\/a:1011984216775.","journal-title":"Pharm Res"},{"key":"3552_CR101","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ejpb.2005.03.002","volume":"60","author":"M Vertzoni","year":"2005","unstructured":"Vertzoni M, Dressman J, Butler J, Hempenstall J, Reppas C. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur J Pharm Biopharm. 2005;60:413\u20137. https:\/\/doi.org\/10.1016\/j.ejpb.2005.03.002.","journal-title":"Eur J Pharm Biopharm"},{"key":"3552_CR102","doi-asserted-by":"publisher","unstructured":"Gowthamarajan K, Singh SK. Dissolution testing for poorly soluble drugs: a continuing perspective. Dissolution Technol. 2010;17:24\u20139. https:\/\/doi.org\/10.14227\/DT170310P24","DOI":"10.14227\/DT170310P24"},{"key":"3552_CR103","doi-asserted-by":"publisher","unstructured":"L\u00f6benberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000;50:3\u201312. https:\/\/doi.org\/10.1016\/s0939-6411(00)00091-6","DOI":"10.1016\/s0939-6411(00)00091-6"},{"key":"3552_CR104","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1208\/s12248-017-0117-1","volume":"19","author":"A Hermans","year":"2017","unstructured":"Hermans A, Abend AM, Kesisoglou F, Flanagan T, Cohen MJ, Diaz DA, et al. Approaches for establishing clinically relevant dissolution specifications for immediate release solid oral dosage forms. AAPS J. 2017;19:1537\u201349. https:\/\/doi.org\/10.1208\/s12248-017-0117-1.","journal-title":"AAPS J"},{"key":"3552_CR105","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.envint.2005.07.004","volume":"32","author":"G-G Ying","year":"2006","unstructured":"Ying G-G. Fate, behavior and effects of surfactants and their degradation products in the environment. Environ Int. 2006;32:417\u201331. https:\/\/doi.org\/10.1016\/j.envint.2005.07.004.","journal-title":"Environ Int"},{"key":"3552_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2020.122299","volume":"392","author":"O Kaczerewska","year":"2020","unstructured":"Kaczerewska O, Martins R, Figueiredo J, Loureiro S, Tedim J. Environmental behaviour and ecotoxicity of cationic surfactants towards marine organisms. J Hazard Mater. 2020;392:122299. https:\/\/doi.org\/10.1016\/j.jhazmat.2020.122299.","journal-title":"J Hazard Mater"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03552-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03552-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03552-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:08:00Z","timestamp":1790705280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03552-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":106,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3552"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03552-x","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the preparation of this manuscript, the authors used generative artificial intelligence (AI)\u2013assisted tools to improve language and readability of the manuscript. All content generated or suggested by these tools was carefully reviewed, verified, and edited by the authors. The authors take full responsibility for the integrity, accuracy, and originality of the work. No generative AI tools were used to generate scientific conclusions, analyze data, or create figures.","order":1,"name":"Ethics","label":"Declaration of Generative AI and AI\u2011Assisted Technologies","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interest. The individual contributors from the referenced industry are employees of their affiliated companies and may own stock.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"315"}}